Empagliflozin vs Dapagliflozin
## Overview
Empagliflozin and dapagliflozin are both SGLT2 inhibitors that reduce glycemic levels by promoting renal glucose excretion. Beyond glucose lowering, both have demonstrated remarkable cardiovascular and renal protective effects that have transformed diabetes management guidelines.
## Mechanism of Action
Both inhibit sodium-glucose cotransporter 2 (SGLT2) in the proximal convoluted tubule, preventing reabsorption of approximately 90% of filtered glucose. This results in glycosuria, osmotic diuresis, natriuresis, and weight loss. Additional mechanisms include reduction of intraglomerular pressure (tubuloglomelular feedback via macula densa), reduction of sympathetic tone, and possible ketone body provision to the heart.
## Pharmacokinetics
Empagliflozin: once daily, bioavailability ~78%, protein binding 86%, hepatic metabolism (glucuronidation), half-life ~12 h. Dapagliflozin: once daily, bioavailability ~78%, protein binding 91%, UGT1A9-mediated glucuronidation, half-life ~12 h. Both are cleared when GFR <45 mL/min/1.73m² (for T2DM glycemic indication), but maintained for CV/renal indication even in CKD.
## Cardiovascular Outcomes
EMPA-REG OUTCOME (empagliflozin): first SGLT2i trial to show CV mortality reduction — 38% reduction in CV death, 35% reduction in HF hospitalizations. DAPA-HF (dapagliflozin): landmark trial extending benefit to HFrEF patients WITHOUT diabetes — 26% reduction in worsening HF or CV death. These distinct trial populations led to different FDA labels: empagliflozin has CV risk reduction indication in T2DM; dapagliflozin has HFrEF indication (with or without diabetes).
## Renal Outcomes
EMPA-KIDNEY (empagliflozin): reduced worsening renal function or renal death by 28% in CKD patients (many without DM). DAPA-CKD (dapagliflozin): 39% reduction in sustained ≥50% eGFR decline, ESRD, renal/CV death in CKD. Both are FDA-approved for CKD.
## Key Takeaways
- Both reduce HbA1c 0.5–1.0%, induce weight loss 2–3 kg, and lower systolic BP 3–5 mmHg
- Empagliflozin: strongest CV mortality data in T2DM (EMPA-REG OUTCOME)
- Dapagliflozin: extended to HFrEF without T2DM (DAPA-HF); CKD without DM (DAPA-CKD)
- Both approved for HF (empagliflozin: EMPEROR-Reduced/Preserved; dapagliflozin: DAPA-HF)
결론
Both empagliflozin and dapagliflozin are first-line agents for T2DM with established ASCVD, HF, or CKD (per ADA 2024 guidelines). Empagliflozin has historically had the strongest CV mortality data; dapagliflozin pioneered the HFrEF-without-diabetes indication. Both are now guideline-recommended across these indications and are essentially interchangeable for most patients.